Real-World study eyes melflufen for Late-Stage myeloma patients
NCT ID NCT07559799
First seen Apr 30, 2026 · Last updated Apr 30, 2026
Summary
This study watches how well the drug melflufen (Pepaxti®) combined with dexamethasone works in everyday medical practice for people with relapsed or refractory multiple myeloma. It includes 50 patients who have already tried at least three other treatments. The goal is to see how often the disease is controlled or shrinks, without giving any experimental treatment—just tracking real-world results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.